A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients : a multicenter validation study
© 2023. The Author(s)..
BACKGROUND: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU.
METHODS: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group.
RESULTS: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways.
CONCLUSIONS: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:24 |
|---|---|
| Enthalten in: |
Respiratory research - 24(2023), 1 vom: 17. Juni, Seite 159 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 19.06.2023 Date Revised 19.06.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12931-023-02462-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358303176 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358303176 | ||
| 003 | DE-627 | ||
| 005 | 20231226074443.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12931-023-02462-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1194.xml |
| 035 | |a (DE-627)NLM358303176 | ||
| 035 | |a (NLM)37328754 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a de Gonzalo-Calvo, David |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A blood microRNA classifier for the prediction of ICU mortality in COVID-19 patients |b a multicenter validation study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.06.2023 | ||
| 500 | |a Date Revised 19.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: The identification of critically ill COVID-19 patients at risk of fatal outcomes remains a challenge. Here, we first validated candidate microRNAs (miRNAs) as biomarkers for clinical decision-making in critically ill patients. Second, we constructed a blood miRNA classifier for the early prediction of adverse outcomes in the ICU | ||
| 520 | |a METHODS: This was a multicenter, observational and retrospective/prospective study including 503 critically ill patients admitted to the ICU from 19 hospitals. qPCR assays were performed in plasma samples collected within the first 48 h upon admission. A 16-miRNA panel was designed based on recently published data from our group | ||
| 520 | |a RESULTS: Nine miRNAs were validated as biomarkers of all-cause in-ICU mortality in the independent cohort of critically ill patients (FDR < 0.05). Cox regression analysis revealed that low expression levels of eight miRNAs were associated with a higher risk of death (HR from 1.56 to 2.61). LASSO regression for variable selection was used to construct a miRNA classifier. A 4-blood miRNA signature composed of miR-16-5p, miR-192-5p, miR-323a-3p and miR-451a predicts the risk of all-cause in-ICU mortality (HR 2.5). Kaplan‒Meier analysis confirmed these findings. The miRNA signature provides a significant increase in the prognostic capacity of conventional scores, APACHE-II (C-index 0.71, DeLong test p-value 0.055) and SOFA (C-index 0.67, DeLong test p-value 0.001), and a risk model based on clinical predictors (C-index 0.74, DeLong test-p-value 0.035). For 28-day and 90-day mortality, the classifier also improved the prognostic value of APACHE-II, SOFA and the clinical model. The association between the classifier and mortality persisted even after multivariable adjustment. The functional analysis reported biological pathways involved in SARS-CoV infection and inflammatory, fibrotic and transcriptional pathways | ||
| 520 | |a CONCLUSIONS: A blood miRNA classifier improves the early prediction of fatal outcomes in critically ill COVID-19 patients | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Biomarker | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a ICU | |
| 650 | 4 | |a Prognosis | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a microRNA | |
| 650 | 7 | |a MicroRNAs |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Molinero, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Benítez, Iván D |e verfasserin |4 aut | |
| 700 | 1 | |a Perez-Pons, Manel |e verfasserin |4 aut | |
| 700 | 1 | |a García-Mateo, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Ortega, Alicia |e verfasserin |4 aut | |
| 700 | 1 | |a Postigo, Tamara |e verfasserin |4 aut | |
| 700 | 1 | |a García-Hidalgo, María C |e verfasserin |4 aut | |
| 700 | 1 | |a Belmonte, Thalia |e verfasserin |4 aut | |
| 700 | 1 | |a Rodríguez-Muñoz, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a González, Jessica |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Gort-Paniello, Clara |e verfasserin |4 aut | |
| 700 | 1 | |a Moncusí-Moix, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Estella, Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Tamayo Lomas, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez de la Gándara, Amalia |e verfasserin |4 aut | |
| 700 | 1 | |a Socias, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Peñasco, Yhivian |e verfasserin |4 aut | |
| 700 | 1 | |a de la Torre, Maria Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Bustamante-Munguira, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Gallego Curto, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez Varela, Ignacio |e verfasserin |4 aut | |
| 700 | 1 | |a Martin Delgado, María Cruz |e verfasserin |4 aut | |
| 700 | 1 | |a Vidal-Cortés, Pablo |e verfasserin |4 aut | |
| 700 | 1 | |a López Messa, Juan |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-García, Felipe |e verfasserin |4 aut | |
| 700 | 1 | |a Caballero, Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Añón, José M |e verfasserin |4 aut | |
| 700 | 1 | |a Loza-Vázquez, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Carbonell, Nieves |e verfasserin |4 aut | |
| 700 | 1 | |a Marin-Corral, Judith |e verfasserin |4 aut | |
| 700 | 1 | |a Jorge García, Ruth Noemí |e verfasserin |4 aut | |
| 700 | 1 | |a Barberà, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Ceccato, Adrián |e verfasserin |4 aut | |
| 700 | 1 | |a Fernández-Barat, Laia |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Gasulla, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Lorente-Balanza, Jose Ángel |e verfasserin |4 aut | |
| 700 | 1 | |a Menéndez, Rosario |e verfasserin |4 aut | |
| 700 | 1 | |a Motos, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Peñuelas, Oscar |e verfasserin |4 aut | |
| 700 | 1 | |a Riera, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Bermejo-Martin, Jesús F |e verfasserin |4 aut | |
| 700 | 1 | |a Torres, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Barbé, Ferran |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Respiratory research |d 2000 |g 24(2023), 1 vom: 17. Juni, Seite 159 |w (DE-627)NLM115627553 |x 1465-993X |7 nnns |
| 773 | 1 | 8 | |g volume:24 |g year:2023 |g number:1 |g day:17 |g month:06 |g pages:159 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12931-023-02462-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 24 |j 2023 |e 1 |b 17 |c 06 |h 159 | ||